12,372 trials
Chronic Hepatitis C
Primary: Percentage of Participants Achieving Sustained Virologic Response 12 Weeks After the End of All Study Therapy (SVR12) — 96.3 percentage of participants
Hepatitis C Infection
Primary: Percentage of Participants Achieving Undetectable HCV RNA 12 Weeks After Completing Study Therapy (SVR12) — 92.4; 94.2; 92.4; 98.1 Percentage of participants — p=<0.001
Diabetes Mellitus
Primary: Baseline Adjusted Hemoglobin A1c Over Time — 9.46; 9.85 percentage of HbA1c — p=0.903
Muscle Wasting · Non Small Cell Lung Cancer
Primary: Physical Function — 29.4; 24.2 percentage of subjects
Pulmonary Disease, Chronic Obstructive
Primary: Change From Baseline in Trough Forced Expiratory Volume in One Second (FEV1) on Treatment Day 85 (Visit 8) — 0.172; 0.171 Liters — p=0.964
Chronic Myeloid Leukemia
Primary: The Percentage of Patients Achieving MMR by 12 Months — 70.8 percentage of participants
Nicotine Addiction
Primary: 7-day Point Prevalence Quit Rate at End-of-Treatment (EOT) — 17.2; 18.6; 27.7; 22.5 percentage of ITT subjects
Metastatic Hormone-sensitive Prostate Cancer
Primary: Overall Survival — 57.6; 44.0 months — p=0.0003
Parkinson's Disease
Primary: Change From Baseline in the Sum of UPDRS Part II + UPDRS Part III — 26.4 units on a scale
Asthma
Primary: Number of Participants With Adverse Events (AEs) Including Both Systemic (i.e. Allergic/Immunoglobulin (Ig)E-mediated and Non-allergic) and Local Site Reactions — 558…
Complicated Urinary Tract Infection (cUTI) Including Acute Pyelonephritis
Primary: Patient-reported Symptomatic Response at Day 5 (mMITT Analysis Set): Non-inferiority Hypothesis Test — 276; 276; 103; 124 Participants
Sleep Disturbances
Primary: Changes From Baseline to Week 8 on Sleep Quality as Assessed by Polysomnographic Recorded (PSG) Parameters — -24.9; -19.7; -26.4; 49.0 minutes (min)
Osteogenesis Imperfecta
Primary: Change in Bone Mineral Density in Response to Pamidronate — -3.54; -4.98 Z-score
Pulmonary Arterial Hypertension
Primary: Time From Randomization to the First Morbidity Event or Death (All Causes) up to 7 Days After the Last Study Drug Intake — 91.2; 81.7; 83.1; 70.6 Percentage of patients…
Chronic Sinusitis With or Without Nasal Polyps
Primary: Adverse Events — 270 participants